Efficacy and safety of dexlansoprazole: a comprehensive review

Authors

  • C. C. Chaubal Digestive and Endoscopy Center, Bhopal, M. P., India
  • Parimal Lawate Gastroenterologist and Hepatologist, Deenanath Mangeshkar Hospital, Pune, Maharashtra, India
  • Sujit Chaudhury Amri Hospitals, Salt Lake, Kolkata, West Bengal, India
  • Ajay Gupta Sarvodaya Hospital, Ghaziabad, Uttar Pradesh, India
  • B. Ravi Shankar Department of Medical Gastroenterology, Yashoda Hospitals, Secunderabad, Telangana, India
  • Sandip Pal Gastroenterologist and Liver Specialist, RNT Hospital, Kolkata, West Bengal, India
  • Sharath Kote G. S. Department of Medical Gastroenterology, Hepatology, and Nutritio, City care Cancer Hospitals, Bangalore, Karnataka, India
  • Dinesh Patil Alembic Pharmaceuticals Ltd. Mumbai, Maharashtra, India

DOI:

https://doi.org/10.18203/2320-6012.ijrms20233741

Keywords:

PPIs, GERD, Food interaction, Dexlansoprazole, Dual delayed-release

Abstract

Gastroesophageal reflux disease (GERD) remains prevalent in medical practice. Proton pump inhibitors (PPIs) are the primary treatment, yet limitations exist. Dexlansoprazole modified release (MR), an R-enantiomer of lansoprazole, offers high efficacy. Its dual release in the duodenum and small intestine yields two peak concentrations at different times (2- and 5-hours post-administration), ensuring the longest maintenance of drug concentration and proton pump inhibitory effect among all PPIs. Dexlansoprazole MR effectively heals erosive esophagitis, maintains healed esophageal mucosa, and controls NERD symptoms. It also improves nocturnal heartburn, GERD-related sleep disturbances, and bothersome regurgitation. Importantly, it maintains good plasma concentration regardless of food intake, enabling flexible dosing. Furthermore, it does not significantly affect clopidogrel metabolism or platelet inhibition, eliminating the need for dose adjustments when co-prescribed. This review highlights dexlansoprazole's unique attributes, pharmacokinetics, advantages, and safety in comparison to traditional PPIs.

 

References

DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol. 2005;100(1):190-200.

Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006;101:1900-20.

El-Serag H, Hill C, Jones R. Systematic review: the epidemiology of gastrooesophageal reflux disease in primary care, using the UK General Practice Research Database. Aliment Pharmacol Ther. 2009;29:470-80.

Fedorak RN, Veldhuyzen van Zanten S, Bridges R. Canadian Digestive Health Foundation Public Impact Series: gastroesophageal reflux disease in Canada: incidence, prevalence, and direct and indirect economic impact. Can J Gastroenterol. 2010;24:431-4.

Dent J, El-Serag HB, Wallander MA, Johansson S. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2005;54:710-7.

Moayyedi P, Axon AT. Review article: gastro-oesophageal reflux disease–the extent of the problem. Aliment Pharmacol Ther. 2005;22(1):11-9.

Jung HK. Epidemiology of gastroesophageal reflux disease in Asia: A systematic review. J Neurogastroenterol Motil. 2011;17:14-27.

Fass R, Shapiro M, Dekel R. Systematic review: proton pump inhibitor failure in gastro-oesophageal reflux disease-where next? Aliment Pharmacol Ther. 2005;22(2):79-94.

Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013;108:308-28.

Fuchs KH, Babic B, Breithaupt W, Dallemagne B, Fingerhut A, Furnee F et al. EAES recommendations for the management of gastroesophageal reflux disease. Surg Endosc. 2014;28(6):1753-73.

Kaltenbach T, Crockett S, Gerson LB. Are lifestyle measures effective in patients with gastroesophageal reflux disease? An evidence-based approach. Arch Intern Med. 2006;166:965-71.

Faria R, Bojke L, Epstein D. Cost-effectiveness of laparoscopic fundoplication versus continued medical management for the treatment of gastro-oesophageal reflux disease based on long-term follow-up of the REFLUX trial. Br J Surg. 2013;100(9):1205-13.

Friedenberg FK, Hanlon A, Vanar V. Trends in gastroesophageal reflux disease as measured by the National Ambulatory Medical Care Survey. Dig Dis Sci 2010;55:1911-7.

Dexilant. Takeda Pharmaceuticals America. Available at: http://www.accessdata.fda.gov/ drugsatfda_docs/label/2016/022287s025_0208056s003lbl.pdf. Accessed on 24 October, 2023.

Nexium. AstraZeneca Pharmaceuticals LP. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/ label/2016/021153s052_22101s016_21957s019lbl.pdf. Accessed December 20, 2016.

Protonix. Pfizer Wyeth Pharmaceuticals Inc. Available at: http://www.accessdata.fda.gov/ drugsatfda_docs/label/2016/020987s050,022020s012lbl.pdf. Accessed 24 October, 2023.

Prevacid. Takeda Pharmaceuticals America, Inc. Available at: http://www.accessdata.fda.gov/ drugsatfda_docs/label/2016/020406s082,021428s030lbl.pdf. Accessed 24 October, 2023.

Aciphex. Eisai Inc., Woodcliff Lake, NJ 07677. Available at: http://www.accessdata.fda.gov/ drugsatfda_docs/label/2016/020973s033lbledt.pdf. Accessed on 4 April, 2023.

Prilosec. AstraZeneca Pharmaceuticals LP. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/ label/2016/019810s103,022056s020lbl.pdf. Accessed on 19 October, 2023.

Sachs G, Shin JM, Briving C, Wallmark B, Hersey S. The pharmacology of the gastric acid pump: the H +,K + ATPase. Annu Rev Pharmacol Toxicol. 1995;35:277-305.

Sachs G, Shin JM, Howden CW. Review article: the clinical pharmacology of proton pump inhibitors. Aliment Pharmacol Ther. 2006;23(2):2-8.

Shin JM, Sachs G. Gastric H, K-ATPase as a drug target. Dig Dis Sci. 2006;51:823-33.

Hunt RH. Review article: the unmet needs in delayed release proton-pump inhibitor therapy in 2005. Aliment Pharmacol Ther. 2005;22(3):10-19.

Hershcovici T, Fass R. Management of gastroesophageal reflux disease that does not respond well to proton pump inhibitors. Curr Opin Gastroenterol. 2010;26:367-78.

Horn JR, Howden CW. Review article: similarities and differences among delayed release proton-pump inhibitor formulations. Aliment Pharmacol Ther. 2005;22(3):20-4.

Stedman CA, Barclay ML. Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Aliment Pharmacol Ther. 2000;14:963-78.

Dickman R, Maradey-Romero C, Gingold- Belfer R. Unmet needs in the treatment of gastroesophageal reflux disease. J Neurogastroenterol Motil. 2015;21:309-19.

Moore JM and Vaezi MF. Extraesophageal manifestation of gastroesophageal reflux disease: real or imagined? Curr Opin Gastroenterol. 2010;26:389-94.

Boparai V, Rajagopalan J, Triadafilopoulos G. Guide to the use of proton pump inhibitors in adult patients. Drugs. 2008;68:925-47.

Lee RD, Vakily M, Mulford D. Clinical trial: the effect and timing of food on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR, a novel dual delayed release formulation of a proton pump inhibitor – evidence for dosing flexibility. Aliment Pharmacol Ther. 2009;29:824-33.

Lee RD, Mulford D, Wu J, Atkinson SN. The effect of time-of-day dosing on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR: evidence for dosing flexibility with a dual delayed release proton pump inhibitor. Aliment Pharmacol Ther. 2010;31:1001-11.

Katsuki H, Yagi H, Arimori K, Nakamura C, Nakano M, Katafuchi S et al. Determination of R (+) and S () lansoprazole using chiral stationary-phase liquid chromatography and their enantioselective pharmacokinetics in humans. Pharm Res. 1996;13(4):611-5.

Behm BW, Peura DA. Dexlansoprazole MR for the management of gastroesophageal reflux disease. Expert Rev Gastroenterol Hepatol. 2011;5:439-45.

Abel C, Desilets AR, Willett K. Dexlansoprazole in the treatment of esophagitis and gastroesophageal reflux disease. Ann Pharmacother. 2010;44:871-6.

Gunaratnam NT, Jessup TP, Inadomi J, Lascewski DP. Sub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastroesophageal reflux disease. Aliment Pharmacol Ther. 2006;23:1473-7.

Kahrilas PJ, Shaheen NS, Vaezi MF. American Gastroenterological Association Institute technical review on the management of gastroesophageal reflux disease. Gastroenterology. 2008;135:1392-413.

Coelho MA, Henry A. Diagnosis and management of gastroesophageal reflux disease. ABCD Arq Bras Cir Dig. 2014;27:210-5.

Moraes-Filho JPP. Doenca do refluxo gastroesofagico de dificiltratamento. RBM Rev Bras Med. 2012;69:41-6.

Savarino V, Savarino E, Parodi A, Pietro D. Functional heartburn and non-erosive reflux disease. Dig Dis. 2007;25:172-4.

Ruigomez A, Johansson S, Wernersson B, Oscar FC, Luis AR. Gastroesophageal reflux disease in primary care using changes in proton pump inhibitor therapy as an indicator of partial response. Scand J Gastroenterol. 2012;47(7):751-61.

Chey WD, Mody RR, Izat E. Patient and physician satisfaction with proton pump inhibitors (PPIs): are there opportunities for improvement? Dig Dis Sci. 2010;55:3415-22.

Hsu PI, Lu CL, Wu DC, Chao-Hung K, Sung-Shuo K, Chun-Chao C et al. Eight weeks of esomeprazole therapy reduces symptom relapse, compared with 4 weeks, in patients with Los Angeles Grade A or B erosive esophagitis. Clin Gastroenterol Hepatol. 2015;13(5):859-66.

Rubenstein JH, Nojkov B, Korsnes S, Adlis SA, Shaw MJ, Weinman B et al. Oesophageal hypersensitivity is associated with features of psychiatric disorders and the irritable bowel syndrome. Aliment Pharmacol Ther. 2007;26(2):443-53.

Dąbrowski A. Farmakoterapia choroby refluksowej. Gastroenterol Prakt. 2012;4:22-8.

Kukulka M, Eisenberg C, Nudurupati S. Comparator pH study to evaluate the single-dose pharmacodynamics of dual delayed-release dexlansoprazole 60 mg and delayed-release esomeprazole 40 mg. Clin Exp Gastroenterol. 2011;4:213-20.

Rohss K, Lind T, Wilder-Smith C. Esomeprazole 40mg provides more effective intragastric acid control than lansoprazole 30mg, omeprazole 20 mg, pantoprazole 40mg and rabeprazole 20mg in patients with gastro-oesophageal reflux symptoms. Eur J Clin Pharmacol. 2004;60:531-9.

Miner PJr, Katz PO, Chen Y, Mark S. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol. 2003;98(12):2616-20.

Lind T, Rydberg L, Kyleback A, A Jonsson, T Andersson, G Hasselgren et al. Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastroesophageal reflux disease. Aliment Pharmacol Ther. 2000;14(7):861-7.

Fass R, Chey WD, Zakko SF, Andhivarothai N, Palmer RN, Perez MC et al. Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease. Aliment Pharmacol Ther. 2009;29(12):1261-72.

Wu MS, Tan SC and Xiong T. Indirect comparison of randomized controlled trials: comparative efficacy of dexlansoprazole vs. esomeprazole in the treatment of gastrooesophageal reflux disease. Aliment Pharmacol Ther. 2013;38:190-201.

Wong WM, Lai KC, Lam KF, Hui WM, Hu WHC, Lam CLK et al. Prevalence, clinical spectrum and health care utilization of gastro-oesophageal reflux disease in a Chinese population: a population-based study. Aliment Pharmacol Ther. 2003;18(6):595-604.

Suzuki H, Matsuzaki J, Okada S, Kenro H, Seiichiro F, Toshifumi H et al. Validation of the GerdQ questionnaire for the management of gastro-oesophageal reflux disease in Japan. United European Gastroenterol J. 2013;1(3):175-83.

Liang CM, Kuo MT, Hsu PI, Chao-Hung K, Wei-Chen T, Shih-Cheng Y et al. First-week clinical responses to dexlansoprazole 60 mg and esomeprazole 40 mg for the treatment of grades A and B gastroesophageal reflux disease. World J Gastroenterol. 2017;23(47):8395-404.

Smout AJPM. Gastro-oesophageal reflux disease. Pathogenesis and diagnosis. In: Champion MC, Orr WC editors. Evolving Concepts in Gastrointestinal Motility. Oxford, England: Blackwell Sci. 1996;46-63.

Van Thiel DH, Gavaler JS, Stremple J. Lower esophageal sphincter pressure in women using sequential oral contraceptives. Gastroenterology. 1976;71(2):232-4.

Metz DC, Vakily M, Dixit T. Review article: dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release proton pump inhibitor therapy. Aliment Pharmacol Ther. 2009;29(9):928-37.

Fass R, Inadomi J, Han C. Maintenance of heartburn relief after step-down from twice-daily proton pump inhibitor to once-daily dexlansoprazole modified release. Clin Gastroenterol Hepatol. 2012;10(3):247-53.

Hershcovici T, Jha LK, Fass R. Dexlansoprazole MR-A review. Ann Med. 2011;43:366-74.

Hansten PD, Horna JR. Top 100 drug interactions 2015. Freeland, H&H Publications. 2014.

Bazire S. Psychotropic drug directory 2014. Dorsington, Lloyd-Reinhold Communications. 2014.

Niu Q, Wang Z, Zhang Y. Combination Use of Clopidogrel and Proton Pump Inhibitors Increases Major Adverse Cardiovascular Events in Patients with Coronary Artery Disease: A Meta-Analysis. J Cardiovascular Pharmacol Therapeutics. 2016.

Wedemeyer RS, Blume H. Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update. Drug Saf. 2014;37:201-211.

BMS. Plavix. Prescribing Information. 2013. Available at: packageinserts.bms.com/pi/pi_plavix.pdf. Accessed on 12 June, 2023.

Peura DA, Metz DC, Dabholkar AH. Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience. Aliment Pharmacol Ther. 2009;30:1010-21.

Fass R. Gastroesophageal Reflux Disease. N Eng J Med. 2022;387(13):1207-16.

Dabholkar AH, Han C, Paris M, Perez MC, Atkinson SN, Peura DA. The 12 month safety profile of dexlansoprazole a proton pump inhibitor with a dual delayed release formulation in patients with gastroesophageal reflux disease. Aliment Pharmacol Ther. 2011;33(3):366-77.

Aslam N, Wright R. Dexlansoprazole MR. Expert Opin Pharmacother. 2009;10(14):2329-36.

Katz PO, Dunbar KB, Schnoll-Sussman FH, Greer KB, Yadlapati R, Spechler SJ. ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease. Am J Gastroenterol. 2022;117(1):27-56.

Li MJ, Li Q, Sun M, Liu LQ. Comparative effectiveness and acceptability of the FDA-licensed proton pump inhibitors for erosive esophagitis: A PRISMA-compliant network meta-analysis. Medicine (Baltimore). 2017;96(39):e8120.

Sharma P, Shaheen NJ, Perez MC, Pilmer BL, Lee M, Atkinson SN et al. Clinical trials: healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation: results from two randomized controlled studies. Aliment Pharmacol Ther. 2009;29(7):731-41.

Emerson CR, Marzella N. Dexlansoprazole: A proton pump inhibitor with a dual delayed-release system. Clin Ther. 2010;32(9):1578-96.

Dumra H, Sainani R, Pratap N, Bhanu PS, Indranil H, Jayesh S et al. Expert Recommendations on Optimizing the Diagnosis and Management of Gastroesophageal Reflux Disease Associated with Comorbidities in the Indian Population. J Assoc Physicians India. 2023;71(8):11-2.

Katz PO, Dunbar KB, Schnoll-Sussman FH, Greer KB, Yadlapati R, Spechler SJ. ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease. Am J Gastroenterol. 2022;117(1):27-56.

Downloads

Published

2023-11-29

How to Cite

Chaubal, C. C., Lawate, P., Chaudhury, S., Gupta, A., Shankar, B. R., Pal, S., S., S. K. G., & Patil, D. (2023). Efficacy and safety of dexlansoprazole: a comprehensive review. International Journal of Research in Medical Sciences, 11(12), 4590–4600. https://doi.org/10.18203/2320-6012.ijrms20233741

Issue

Section

Review Articles